Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Research Council grant · Running

Uro-Lieve Uro-Lieve: Slow-Release Capsaicin Hydrogel for Disease-Modifying Therapy of Painful Bladder Syndrome

Coordinator
University of Galway, Ireland
Runs
1 June 2026 to 30 November 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101293238

What the project is doing

In the project's own words, from its summary on CORDIS.

Painful Bladder Syndrome/Interstitial Cystitis (IC/BPS) is a chronic, debilitating pelvic pain condition that affects millions of predominantly female patients and lacks an effective, long-lasting therapy. Existing treatments—including oral drugs, intravesical instillations, and neuromodulation—are largely palliative, short-lived, or poorly tolerated. A promising therapeutic approach based on selective desensitisation of bladder pain fibres has shown prolonged analgesic potential in clinical studies, but clinical adoption has been limited by the intense discomfort associated with administration.

Uro-Lieve overcomes this barrier with a biodegradable injectable hydrogel that enables controlled, sustained local delivery of a potent neuromodulatory agent. This approach minimises acute discomfort while ensuring durable sensory desensitisation, enabling a minimally invasive, potentially disease-modifying treatment. Over 18 months, the project will optimise the hydrogel formulation, demonstrate in vivo efficacy and safety, and prepare a complete regulatory, intellectual-property, and commercialisation package.

By addressing a major unmet medical need and aligning with EU priorities on women’s health and gender equality, Uro-Lieve has the potential to transform chronic bladder pain management, reduce healthcare costs, and establish a scalable platform for other visceral pain disorders. This ERC Proof of Concept will deliver a patent-protected, investor-ready technology positioned for rapid first-in-human trials and market translation.

Topics

Who is involved

OrganisationCityCountryRole
University of GalwayGalwayIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI